PF
BCLI

Phoenix Financial’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Phoenix Financial’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,788
Closed -$214K – 312
2021
Q1 		$214K Sell
3,788
-7,791
-67% -$588K ﹤0.01% 385
2020
Q4 		$799K Buy
+11,579
New +$1.58M 0.02% 238
2020
Q3 		– Sell
-6,985
Closed -$1.11M – 335
2020
Q2 		$1.11M Sell
6,985
-917
-12% -$98.9K 0.05% 197
2020
Q1 		$534K Buy
7,902
+5,964
+308% +$465K 0.03% 239
2019
Q4 		$124K Sell
1,938
-526
-21% -$30.5K 0.01% 191
2019
Q3 		$138K Buy
+2,464
New +$145K 0.01% 185

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Phoenix Financial's BCLI Position: Q2 2021 in Review

Phoenix Financial sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 3,788 shares — an estimated $214K sold.

Phoenix Financial first reported a position in BCLI in Q3 2019 and held it in 6 quarters. The position peaked at $1.11M in Q2 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • Phoenix Financial reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • Phoenix Financial sold 3,788 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $214K.
  • Phoenix Financial first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2019 and held it in 6 quarters.
  • Phoenix Financial's BRAINSTORM CELL THERAPUTC position peaked at $1.11M in Q2 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on Phoenix Financial's 13F filing for Q2 2021, filed 10 Aug 2021.